David A. Siegel Biotechnology

Two Sigma Advisers, LP

$47 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
REGN Regeneron Pharmaceuticals, Inc.	$74.3B	$521 Million 1.11% of portfolio	926,200	Q3 2025 Reduced 1.31%
ALNY Alnylam Pharmaceuticals, Inc.	$55.3B	$407 Million 0.87% of portfolio	892,500	Q3 2025 Added 235.4%
MRNA Moderna, Inc.	$9.69B	$175 Million 0.37% of portfolio	6,772,900	Q3 2025 Reduced 13.34%
IONS Ionis Pharmaceuticals Inc	$10.2B	$136 Million 0.29% of portfolio	2,073,111	Q3 2025 Reduced 22.29%
ARGX Argenx Se	$50.2B	$103 Million 0.22% of portfolio	139,700	Q3 2025 Added 897.86%
BBIO Bridge Bio Pharma, Inc.	$9.84B	$86.4 Million 0.18% of portfolio	1,662,755	Q3 2025 Reduced 1.26%
HALO Halozyme Therapeutics, Inc.	$9.75B	$44.7 Million 0.1% of portfolio	610,000	Q3 2025 Added 113.74%
GMAB Genmab A/S	$19.9B	$43.9 Million 0.09% of portfolio	1,432,800	Q3 2025 Reduced 21.32%
VKTX Viking Therapeutics, Inc.	$3.05B	$39.7 Million 0.08% of portfolio	1,555,128	Q3 2025 Added 42.49%
SRPT Sarepta Therapeutics, Inc.	$1.65B	$37.7 Million 0.08% of portfolio	1,958,034	Q3 2025 Reduced 1.39%
NTLA Intellia Therapeutics, Inc.	$661M	$37.4 Million 0.08% of portfolio	2,163,417	Q3 2025 Added 3.36%
CRSP Crispr Therapeutics Ag	$4.1B	$37.1 Million 0.08% of portfolio	572,972	Q3 2025 Reduced 57.39%
BCRX Biocryst Pharmaceuticals Inc	$1.32B	$32.2 Million 0.07% of portfolio	4,240,712	Q3 2025 Added 0.29%
ABCL Ab Cellera Biologics Inc.	$1.05B	$24.1 Million 0.05% of portfolio	4,799,900	Q3 2025 Added 17.92%
QURE Uni Qure N.V.	$1.4B	$23.9 Million 0.05% of portfolio	409,500	Q3 2025 Reduced 37.93%
LEGN Legend Biotech Corp	$5.07B	$23.6 Million 0.05% of portfolio	723,700	Q3 2025 Added 1.06%
RPRX Royalty Pharma PLC	$17.1B	$23.2 Million 0.05% of portfolio	657,200	Q3 2025 Reduced 22.4%
KYMR Kymera Therapeutics, Inc.	$3.55B	$21.1 Million 0.04% of portfolio	372,400	Q3 2025 Added 66.03%
MIRM Mirum Pharmaceuticals, Inc.	$2.63B	$20.3 Million 0.04% of portfolio	276,400	Q3 2025 Added 61.26%
TVTX Travere Therapeutics, Inc.	$2.21B	$16.7 Million 0.04% of portfolio	696,700	Q3 2025 Reduced 34.13%
RARE Ultragenyx Pharmaceutical Inc.	$2.32B	$15.6 Million 0.03% of portfolio	517,700	Q3 2025 Reduced 39.83%
TGTX Tg Therapeutics, Inc.	$4.5B	$15.5 Million 0.03% of portfolio	428,200	Q3 2025 Added 246.72%
IMCR Immunocore Holdings PLC	$1.58B	$12 Million 0.03% of portfolio	330,000	Q3 2025 Reduced 35.6%
MNKD Mannkind Corp	$1.3B	$9.83 Million 0.02% of portfolio	1,831,327	Q3 2025 Reduced 45.93%
XNCR Xencor Inc	$891M	$9.5 Million 0.02% of portfolio	810,200	Q3 2025 Added 39.86%
ARDX Ardelyx, Inc.	$908M	$8.91 Million 0.02% of portfolio	1,614,600	Q3 2025 Added 30.58%
BEAM Beam Therapeutics Inc.	$1.53B	$8.08 Million 0.02% of portfolio	333,000	Q3 2025 Reduced 39.79%
INSM Insmed Inc	$26.2B	$7.39 Million 0.02% of portfolio	51,300	Q3 2025 Added 193.14%
XERS Xeris Biopharma Holdings, Inc.	$986M	$7.24 Million 0.02% of portfolio	893,242	Q3 2025 Reduced 15.48%
AVXL Anavex Life Sciences Corp.	$284M	$6.75 Million 0.01% of portfolio	758,500	Q3 2025 Reduced 7.88%
NVO Novo Nordisk A S	$109B	$6.64 Million 0.01% of portfolio	119,600	Q3 2025 Reduced 91.41%
ASND Ascendis Pharma A/S	$11.4B	$6.54 Million 0.01% of portfolio	32,900	Q3 2025 New
SNDX Syndax Pharmaceuticals Inc	$940M	$5.9 Million 0.01% of portfolio	383,052	Q3 2025 Reduced 2.4%
RLAY Relay Therapeutics, Inc.	$756M	$5.87 Million 0.01% of portfolio	1,124,300	Q3 2025 Reduced 1.36%
RCKT Rocket Pharmaceuticals, Inc.	$231M	$5.85 Million 0.01% of portfolio	1,795,751	Q3 2025 Added 20.5%
ALT Altimmune, Inc.	$204M	$5.39 Million 0.01% of portfolio	1,428,400	Q3 2025 Added 1,005.57%
AUPH Aurinia Pharmaceuticals Inc.	$2.18B	$5.3 Million 0.01% of portfolio	479,900	Q3 2025 Added 169.61%
LQDA Liquidia Corp	$1.84B	$5.26 Million 0.01% of portfolio	229,400	Q3 2025 Reduced 29.28%
CORT Corcept Therapeutics Inc	$8.09B	$4.94 Million 0.01% of portfolio	59,400	Q3 2025 Reduced 54.34%
GOSS Gossamer Bio, Inc.	$255M	$4.92 Million 0.01% of portfolio	1,870,100	Q3 2025 Added 11.83%
MRVI Maravai Lifesciences Holdings, Inc.	$479M	$4.74 Million 0.01% of portfolio	1,651,400	Q3 2025 Reduced 25.77%
FDMT 4 D Molecular Therapeutics, Inc.	$351M	$4.63 Million 0.01% of portfolio	549,700	Q3 2025 Reduced 26.06%
VNDA Vanda Pharmaceuticals Inc.	$246M	$4.54 Million 0.01% of portfolio	909,300	Q3 2025 Added 12.37%
VRTX Vertex Pharmaceuticals Inc	$112B	$4.5 Million 0.01% of portfolio	11,500	Q3 2025 Added 1,177.78%
EDIT Editas Medicine, Inc.	$179M	$4.18 Million 0.01% of portfolio	1,205,000	Q3 2025 Added 28.11%
RXRX Recursion Pharmaceuticals, Inc.	$747M	$3.98 Million 0.01% of portfolio	815,445	Q3 2025 New
RCUS Arcus Biosciences, Inc.	$1.45B	$3.88 Million 0.01% of portfolio	285,400	Q3 2025 Reduced 3.52%
ETON Eton Pharmaceuticals, Inc.	$428M	$3.69 Million 0.01% of portfolio	168,900	Q3 2025 Added 67.39%
ALLO Allogene Therapeutics, Inc.	$177M	$3.45 Million 0.01% of portfolio	2,781,600	Q3 2025 Added 57.38%
KOD Kodiak Sciences Inc.	$1.02B	$3.43 Million 0.01% of portfolio	209,400	Q3 2025 Reduced 6.77%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account